Recent advances in optimizing siRNA delivery to hepatocellular carcinoma cells

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally.
• Existing therapies for HCC, especially advanced stages, show limited efficacy.
• Small-interfering RNA (siRNA) presents a promising therapeutic strategy for HCC by inhibiting oncogenic gene expression.

Purpose of the Study:

• To review recent advancements in siRNA delivery systems for HCC.
• To focus on lipid and polymeric nanoparticles for targeted HCC therapy.
• To identify challenges and future directions in nanoparticle-based siRNA delivery for liver cancer.

Main Methods:

• Comprehensive literature review of studies published in the last five years.
• Analysis of lipid and polymeric nanoparticle formulations for siRNA delivery.
• Evaluation of targeting strategies and delivery mechanisms for HCC.

Main Results:

• Nanoparticle-based delivery systems are crucial for protecting siRNA from degradation and enabling targeted delivery to HCC.
• Lipid and polymeric nanoparticles show potential for effective siRNA delivery, but challenges remain.
• Optimization of nanoparticle characteristics is key for enhanced therapeutic outcomes.

Conclusions:

• Targeted delivery of siRNA using advanced nanoparticle systems is essential for effective HCC treatment.
• Future research should focus on optimizing nanoparticles for improved tumor penetration and cellular uptake.
• Nanoparticle engineering, including size optimization and surface functionalization with targeting ligands, is critical for advancing siRNA-based HCC therapies.